Cagrilintide / Semaglutide Mix.
About Cagrilintide / Semaglutide Mix
Cagrilintide / Semaglutide Mix is among the compounds studied in metabolic and weight-regulation research. Dual activation of the GLP-1 receptor (semaglutide) and the amylin receptor (cagrilintide), simultaneously engaging two independent satiety-signaling pathways that converge in the brainstem.
Research Application
In REDEFINE-1 (n=3,417; obesity/overweight without diabetes), CagriSema produced 22.7% mean weight loss at 68 weeks versus 16.1% for semaglutide alone, 11.8% for cagrilintide alone, and 2.3% for placebo. In REDEFINE-2 (type 2 diabetes), weight loss was 13.7% vs. 3.4% for placebo.
Important to know
Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.
Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.
Research Overview
A growing number of preclinical and clinical studies exist for metabolic peptides, though the volume varies significantly by substance.
- Garvey WT, et al. N Engl J Med. 2025;393(6):499–513. PMID 40544433
- Rosenstock J, et al. N Engl J Med. 2025;393(7).
References without a PMID can be located via the respective publisher. This overview does not claim to be exhaustive.
Similar Peptides
Question about Cagrilintide / Semaglutide Mix?
We reply personally – via email or Telegram.